Last reviewed · How we verify
Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease (MSCSecretome)
This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of topical MSC Secretome eye drops. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use anterior segment Optical Coherence Tomography (OCT)/Scheimpflug Imaging, esthesiometry, and visual analogue scale (VAS) to assess treatment tolerability.
Details
| Lead sponsor | University of Illinois at Chicago |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | COMPLETED |
| Enrolment | 9 |
| Start date | Wed Jan 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Nov 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Mesenchymal Stromal Cells
- Cornea
- Corneal Defect
- Corneal Epithelium Defect
Interventions
- MSC Secretome Eye Drops
Countries
United States